Innovations

HIV/AIDS continues to disproportionately impact sub-Saharan Africa, where it remains a leading cause of illness and death among children. Paediatric HIV progresses at an alarming rate, with 20–30% of untreated infants succumbing to the disease within their first year. Without timely intervention

Drug regimens have not been optimised for individuals of African descent. This is due to several converging factors, including Africa’s diverse genetics, disproportionate disease burdens (and consequently a high dependency on specific drug regimens), as well as under-representation of local

Monoclonal antibodies (mAbs) are immune system proteins that are used in targeted drug therapy and prophylaxis and are in high demand around the world to fight diseases. Despite advancements in biomedical technology, current methods for producing mAbs – primarily mammalian cell cultures – can be